OREVO Fuels converts municipal wastewater sludge into fossil-identical renewable diesel and SAF using Corazyme™, a proprietary enzymatic platform. No new infrastructure. No combustion. No agricultural feedstocks. Deployable within 6 months of pilot agreement. Bench-validated and raising a $10M Series A.
Municipal and industrial facilities generate sludge continuously. Already collected on-site. No feedstock logistics, no procurement cost, no agricultural land use. The input is the liability cities already pay to remove.
Corazyme™ uses a proprietary enzyme system to convert biogenic carbon at ambient temperature and pressure. No gasification, no combustion, no high-energy input required. Modular unit retrofits directly to existing wastewater infrastructure.
Specification-compliant renewable diesel for immediate sale or on-site use. SAF-compatible molecules follow ASTM D7566 certification pathway. Carbon credits generated per gallon from day one of operation.
Example based on ~300K population facility (Minneapolis MET Council scale)
| Annual fuel output | 505,890 gallons |
| Production cost / gallon | $0.51 — $1.70 |
| Market price / gallon | $8.78 |
| Annual revenue | $4.4M |
| Gross margin | ~94% |
| With 45Z uplift / gallon | $10.30 — $10.50 |
| 5-module revenue | $22.2M |
| 5-module gross profit | $20.8M |
Fuel sales only. Additional revenue lines (licensing, enzyme supply, carbon credits) materially increase total site value. Larger systems serving 3M+ population support ~10x output.
Diesel, SAF, and gasoline compatible with all existing pipelines, refineries, and engines. No downstream modifications.
Modular unit attaches to existing treatment facilities. Low CapEx. Rapid installation. Minimal site disruption.
No combustion, no gasification, no high-energy inputs. Enzymatic process runs at ambient temperature and pressure.
CI profile meets 45Z threshold. Drives materially higher per-module EBITDA and strengthens strategic buyer economics.
Every U.S. city generates sludge continuously. No foreign supply chain exposure. Stable, low-cost, high-volume input.
No food-grade inputs, no farmland use, no synthetic fuel dependency. Real waste, not competing land or crop resources.
Municipal wastewater utilities
Industrial operators (food & beverage)
Airports & on-site fuel demand
U.S. military installations
State decarbonization programs
OREVO is a biotech infrastructure company that transforms municipal wastewater into fossil-identical fuels via Corazyme™. The platform integrates into existing infrastructure to produce drop-in fuel without new construction, enabling decarbonization without disruption.
A modular, retrofittable enzymatic system that converts wastewater sludge into fossil-identical fuels. Includes proprietary conversion technology, consumable enzymes, licensing, and performance tracking for fuel generation and carbon credit creation.
Most alternatives require synthetic inputs or capital-intensive redesign. Corazyme™ operates at ambient conditions with minimal inputs, delivering low-cost, low-carbon fuels from systems already in place. No food-grade feedstocks.
Revenue through fuel sales, technology licensing, enzyme supply, and carbon credit monetization. Each stream scales independently while reinforcing platform value. Fuel offtake agreements secure recurring EBITDA from day one of operation.
| Company | Modular deployment | No combustion | Non-food feedstock | No new construction | Drop-in compatible | Immediate revenue |
|---|---|---|---|---|---|---|
| Corazyme™ / OREVO Fuels | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| LanzaJet | — | — | ✓ | — | ✓ | — |
| Fulcrum Bioenergy | — | — | ✓ | — | ✓ | — |
| Gevo | — | ✓ | — | — | ✓ | — |
| Traditional biofuel | — | — | — | — | ✓ | — |
Enzymatic platform validated. IP secured. Yield and cost profile confirmed. Patent application submitted.
CompleteActive conversations in Minneapolis, Vacaville, and Seattle. MOUs signed. DOE SBIR and ITV grants submitted.
In progressFirst commercial module build funded by Series A. Site integration, fuel qualification, first offtake agreements.
Series A35 modules in 7 years. $154M revenue, $86M EBITDA. Strategic exit to energy major at $688M–$2.15B.
Year 7Molecular biologist with deep experience in enzymatic system engineering and industrial biomanufacturing. Led R&D teams, secured IP across biotech and plant genetics, and contributed to over $450M in successful exits. Drives technical direction and Corazyme™ commercial readiness.
Business development leader with background in regulated infrastructure and multi-year commercial partnerships. Compliance expert for large human services systems and recurring contract negotiation track record for multi-site business models. Leads commercialization and buyer engagement.
Pilot validation and early revenue through fuel offtake, licensing, and carbon market entry. IP-protected process and modular format reduce friction, allowing scale without infrastructure expansion.
Pilot launches with municipal or industrial partner, supporting validation and case study development. Future sales driven through direct partnerships and public funding opportunities including SBIR and DOE grants.
Initial customers include fuel buyers, airports, wastewater operators, and large energy consumers. Platform designed to scale into logistics, utilities, and government markets including U.S. military installations.
Energy majors deploying billions into SAF and low-carbon fuels. Chevron ($3B+), BP ($4B+), Shell ($10B+), ExxonMobil ($17B+). Corazyme™ aligns directly with acquisition theses around feedstock, CI, and scalability.